Patents Examined by Emily Bernhardt
  • Patent number: 10851075
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: December 1, 2020
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Patent number: 10851125
    Abstract: The present invention relates to novel forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate, pharmaceutical formulations, and therapeutic uses thereof in treating viral infections (e.g., an HIV infection).
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: December 1, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Olga Viktorovna Lapina, Bing Shi, Silas Wang
  • Patent number: 10849895
    Abstract: Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: December 1, 2020
    Assignee: LANDOS BIOPHARMA, INC.
    Inventors: Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
  • Patent number: 10844038
    Abstract: This invention provides compounds of the formula (I): wherein Y1, Y2, Z, X1, X2, and W? are defined in the specification. These compounds are useful in the treatment of tyrosine kinases, MAPK signaling pathway kinases and PI3K/AKT/mTor signaling pathway kinases-mediated diseases or conditions, such as neurodegeneration, neuroprotection, cancer, autoimmune as well as other diseases and conditions associated with the modulation of tyrosine kinases selected from FYN, FYN Y531F, FLT3, FLT3-ITD, BRK, ITK, FRK, BTK, BMX, SRC, FGR, YES1, LCK, HCK, RET, CSK, LYN, and ROS1; MAPK pathway kinases selected from ARAF, BRAF, CRAF, ERK1/2, MEK1, MEK2, MEK3, MEK4, MEK5, MEK6, and MEK7; and PI3K/AKT/mTor pathway kinases: selected from mTor, PI3K ?, PI3K ?, PI3K ?, and PI3K ?.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: November 24, 2020
    Assignee: SABILA BIOSCIENCES LLC
    Inventors: Tarek S. Mansour, Colleen E. Evans
  • Patent number: 10836765
    Abstract: The present invention relates to an improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: November 17, 2020
    Assignee: Aurobindo Pharma Ltd
    Inventors: Sandeep Jain, Komel Ansari, Subramanyam Maddala, Sivakumaran Meenakshisundaram
  • Patent number: 10836782
    Abstract: The present invention provides mito-honokiol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol compounds in the treatment of cancer.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: November 17, 2020
    Assignees: The Medical College of Wisconsin, Inc., Aix-Marseille Universite
    Inventors: Balaraman Kalyanaraman, Jacek Michal Zielonka, Micael J. Hardy, Oliver Ouari, Ming You
  • Patent number: 10836751
    Abstract: The present application provides a method for preparing nintedanib. The method of the present application is carried out by using 4-halo-3-nitro-benzoic acid methyl ester (compound II) and 3-oxo-3-phenylpropionate (compound III) as raw materials, and preparing nintedanib via intermediates of methyl 4-(1-alkoxy-1,3-dioxo-3-phenyl propan-2-yl)-3-nitrobenzoate (compound IV) and methyl 3-benzoyl-2-oxoindoline-6-formate (compound V). The method for preparing nintedanib (I) provided by the present application has the advantages of using easily obtained raw materials, having a simple process, being cost effective and environmentally friendly, and is suitable for industrial-scale production.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: November 17, 2020
    Assignees: Zhejiang Huahai Pharmaceutical Co., Ltd., Shanghai Syncores Technologies, Inc.
    Inventors: Zeng Li, Xiaosong Cheng, Xianliang He, Jicheng Zhang, Luning Huang, Anping Tao, Hong Gu
  • Patent number: 10829493
    Abstract: The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFR? and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFR?. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: November 10, 2020
    Assignee: Blueprint Medicines Corporation
    Inventor: Thomas A. Dineen
  • Patent number: 10822338
    Abstract: The present invention is directed to compounds of generic formula (I): or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. The invention is further directed to methods of treating a patient (preferably a human) for diseases or disorders in which the A2A-receptor is involved. The invention further involves use of the compounds as an A2A-receptor antagonist and/or inhibitor for the preparation of a medicament for the treatment and/or prevention of diseases associated with inhibiting the receptor, which includes central nervous system disorders such as Parkinson's disease. The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: November 3, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Xianhai Huang, Yeon-Hee Lim, Rongze Kuang, Heping Wu, Rajan Anand, Younong Yu, Edward Metzger, Michael Man-Chu Lo, Pauline C. Ting, Andrew W. Stamford, Paul Tempest
  • Patent number: 10822312
    Abstract: The present disclosure provides inhibitors of Ras protein of Formula (I-A): Also disclosed are methods to modulate the activity of Ras protein and methods of treatment of disorders mediated by Ras protein with compounds of Formula (I-A).
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: November 3, 2020
    Assignee: ARAXES PHARMA LLC
    Inventors: Liansheng Li, Jun Feng, Pingda Ren, Yi Liu
  • Patent number: 10806723
    Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 20, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mukesh Agarwal, David Wald, Mahesh Gundluru, Goutam Karan, Zhiqiang Xia
  • Patent number: 10800754
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 13, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Masato Yoshida, Shinichi Imamura
  • Patent number: 10800763
    Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: October 13, 2020
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Walter Cabri, Saswata Lahiri, Bhuwan Bhaskar Mishra, Abul Azim, Nilendu Panda, Poli Reddy Bhavanam, Krishanu Ray, Nikunj Kachhadia, Kumber Singh
  • Patent number: 10800785
    Abstract: Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: October 13, 2020
    Assignees: Shanghai Fochon Pharmaceutical Co., Ltd., Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong Zhao, Weipeng Zhang, Zhifang Chen, Ling Chen, Xianlong Wang, Zhifu Li, Rui Tan, Lijun Yang, Haohan Tan, Bin Liu, Kai Ran, Zongyao Zou, Min Lin, Jing Sun, Weibo Wang
  • Patent number: 10800777
    Abstract: The present disclosure relates to crystalline forms of venetoclax and process for their preparation. The present disclosure also relates to process for preparation of amorphous venetoclax.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 13, 2020
    Assignee: Mylan Laboratories Limited
    Inventors: Ramakoteswara Rao Jetti, Hemant Malhari Mande, Anjaneyaraju Indukuri, Narasimha Murthy Pilli, Rajesh Joshi, Anil Kumar Tripathi, Chandrakant Chaudhri, Kiran Pokharkar, Nagaraju Gottumukkala
  • Patent number: 10800762
    Abstract: This invention relates to compounds which are used in the preparation of the compound of formula (II).
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: October 13, 2020
    Assignee: PULMOCIDE LIMITED
    Inventors: Mihiro Sunose, Thomas Christopher Colley, Kazuhiro Ito, Garth Rapeport, Peter Strong
  • Patent number: 10793575
    Abstract: An oxoisoquinoline compound of the following formula: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the oxoisoquinoline compound or salt; and a method for treating B-cell lymphoma comprising administering the oxoisoquinoline compound or salt to a patient.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: October 6, 2020
    Assignee: CARNA BIOSCIENCES, INC.
    Inventors: Wataru Kawahata, Takao Kiyoi, Takayuki Irie, Tokiko Asami, Masaaki Sawa, Shigeki Kashimoto
  • Patent number: 10787473
    Abstract: Disclosed is a pH-responsive fluorescent compound, represented by the general formula, which is a novel pH-responsive fluorescent compound capable of being specifically localized in mitochondria within cells, which exhibits strong fluorescence under weakly acidic pH environments in lysosomes, and which is not readily subject to interference from autofluorescence and background fluorescence due to other fluorescent substances within cells. Also disclosed are a composition for detecting mitophagy using the pH-responsive fluorescent compound, and a method for detecting mitophagy within cells. In the general formula, L represents a linker, X represents a pharmaceutically acceptable anion, and Y represents a reactive group that may react with a functional group on a mitochondrial protein to form a covalent bond.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: September 29, 2020
    Assignee: DOJINDO LABORATORIES
    Inventors: Hidefumi Iwashita, Ryo Sakamoto, Munetaka Ishiyama
  • Patent number: 10784447
    Abstract: The present invention relates to: an organic compound represented by Chemical Formula 1; a composition for an organic optoelectronic diode containing the organic compound; and an organic optoelectronic diode to which the organic compound or the composition is applied. In Chemical Formula 1, Z, R1 to R11, and n1 to n4 are the same as those defined in the specification.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 22, 2020
    Assignee: SAMSUNG SDI CO., LTD.
    Inventors: Sujin Han, Dong Min Kang, Soohyun Min, Eun Sun Yu, Byoungkwan Lee, Hanill Lee, Sung-Hyun Jung, Ho Kuk Jung
  • Patent number: 10781214
    Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: September 22, 2020
    Assignee: PRECEDO PHARMACEUTICALS CO., LTD.
    Inventors: Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Hong Wu, Kailin Yu, Chen Hu, Wenchao Wang, Cheng Chen, Fengming Zou, Ziping Qi, Li Wang, Beilei Wang